Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000006)
SBP Name
Affibody ABY-029
Synonyms
ABY029; IRDye? 800CW Maleimide labeled Affibody peptide
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase I
Protein Scaffold Information of This SBP
Scaffold ID PS004
Scaffold Info
[1] , [2]
Scaffold Name Affibody
Scaffold Class Non-Antibody
Fold Type Three Alpha-Helices
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Epidermal growth factor receptor
BTS Info
Binder Cancers [ICD-11: 2D4Z] Kd: 3 nM Affibody AB [1] , [2]
Clinical Trial Information of This SBP
NCT02901925 Click to show the Detail
Indication Recurrent Glioma
Phase Phase I
Title A Phase 0 Open Label, Single-center Clinical Trial of?ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Recurrent Glioma
Status Recruiting
Sponsor Dartmouth-Hitchcock Medical Center
NCT03154411 Click to show the Detail
Indication Primary Sarcoma
Phase Phase I
Title A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Primary Sarcoma.
Status Recruiting
Sponsor Dartmouth-Hitchcock Medical Center
NCT03282461 Click to show the Detail
Indication Operable Head and Neck Cancer
Phase Phase I
Title A Phase 0 Open Label, Single-center Clinical Trial of?ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Operable Head and Neck Cancer.
Status Recruiting
Sponsor Dartmouth-Hitchcock Medical Center
References
1 Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use. Mol Imaging Biol. 2017 Aug;19(4):512-521.
2 AffibodyAB. Product Development Pipeline. 2021.